CD79B and diffuse large B-cell lymphoma: In 2019, compound 7, a second ADC of MMAE whose mAbtargets CD79b (B-cell antigen receptor complex-associated proteinβ chain), was granted accelerated FDA approval for the treatmentof adults with relapsed or refractory diffuse large B-cell lymphoma(DLBCL) in combination with bendamustine plus rituximab (BR).72 A multicenter phase Ib/II clinical trial includinga cohort of 80 patients with relapsed or refractory DLBCL [NCT02257567]granted drug approval.